MOVETIS
Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is a... lso tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.
MOVETIS
Industry:
Biotechnology Health Care Medical
Founded:
2006-01-01
Address:
Turnhout, Antwerpen, Belgium
Country:
Belgium
Website Url:
http://www.movetis.com
Total Employee:
11+
Status:
Active
Contact:
32 1 440 43 90
Total Funding:
63.79 M USD
Technology used in webpage:
SPF Amazon AWS Global Accelerator
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Novacta Biosystems
Novacta Biosystems develops and markets drugs for the treatment of bacterial infections, especially those caused by drug resistant bacteria.
Current Advisors List
Current Employees Featured
Founder
Investors List
Quest for Growth
Quest for Growth investment in Series A - Movetis
Gimv
Gimv investment in Series A - Movetis
Sofinnova Partners
Sofinnova Partners investment in Series A - Movetis
BIP Investment Partners
BIP Investment Partners investment in Series A - Movetis
Life Sciences Partners
Life Sciences Partners investment in Series A - Movetis
KBC
KBC investment in Series A - Movetis
Sofinnova Investments
Sofinnova Investments investment in Series A - Movetis
Sofinnova Investments
Sofinnova Investments investment in Venture Round - Movetis
Official Site Inspections
http://www.movetis.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 13.248.169.48
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Movetis"
Movetis - Crunchbase Company Profile & Funding
Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its …See details»
Movetis - EQT Group
Latest news. 03 October 2024 Invitation to presentation of EQT AB’s Q3 Announcement 2024; 02 October 2024 EQT Broadens Reworld™ Investor Base, Welcoming GIC as Strategic InvestorSee details»
Movetis - Wikipedia
Movetis was a pharmaceutical company headquartered in Belgium. It was founded in 2006 as a spin-off from parent company Johnson & Johnson. The company specialized in pharmaceuticals for treating gastro-intestinal disorders. The primary drug produced by Movetis was Prucalopride (known by the brand name "Resolor"), indicated for cases of chronic constipation. See details»
Movetis — Sofinnova Partners
Movetis focused on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. It was created by a team of entrepreneurs led by …See details»
Movetis Company Profile 2024: Valuation, Investors, Acquisition
Information on acquisition, funding, cap tables, investors, and executives for Movetis.See details»
Movetis NV - VentureRadar
Gastro intestinal speciality pharma company ... Find out more about Movetis NV, Life Sciences, Drug Development, Biopharmaceuticals and Healthtech and Life Sciences.See details»
Movetis - Company Profile and News - Bloomberg Markets
Shire-Movetis NV manufactures pharmaceutical products. The Company develops products for gastrointestinal areas including ascites, pediatric reflux, refractory gastroesophageal reflux...See details»
Movetis NV - Turnhout, Belgium - bionity.com
Oct 5, 2010 · MOVETIS is developing their portfolio of eight products and two discovery platforms which are concentrated on important areas of unmet medical need, including severe, chronic …See details»
Movetis - Funding, Financials, Valuation & Investors - Crunchbase
Movetis is focused on the development of drugs for the treatment of diseases in the gastrointestinal area.See details»
Movetis - Crunchbase
Movetis is focused on the development of drugs for the treatment of diseases in the gastrointestinal area.See details»
movetis.com
Movetis.comSee details»
Venture capitalists re-emerge for Movetis IPO - Financial Times
Dec 4, 2009 · A two-year drought of initial public offerings by venture capital-backed companies in Europe will be broken on Friday when Movetis, a developer of gastrointestinal drugs, will raise …See details»
Shire to Acquire Movetis NV - Pharmaceutical Processing World
Aug 3, 2010 · Shire plc, the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public …See details»
BioCentury - Moving On
Aug 9, 2010 · Since being spun out from Johnson & Johnson (NYSE:JNJ) three-plus years ago, Movetis has raised a single private round, got its lead product approved, completed the …See details»
BioCentury - Shire Early and Late
Aug 9, 2010 · Shire plc's proposed acquisition of Movetis N.V. fits one arm of the company's growth strategy by acquiring near-to-market or marketed products for specialty indications.See details»
Movetis - Contacts, Employees, Board Members, Advisors & Alumni
Movetis is focused on the development of drugs for the treatment of diseases in the gastrointestinal area.See details»
Movetis’ Board Welcomes Shire’s €428M Cash Takeover Bid
Aug 3, 2010 · Shire has made a €428 million (about $549 million) cash bid for Belgian gastrointestinal (GI) disorder therapeutics firm Movetis in order to acquire the firm’s marketed …See details»
Movetis seeking up to 112.4 million euros in IPO | Reuters
BRUSSELS, Nov 20 (Reuters) - Belgian drugmaker Movetis said it could raise up to 112.4 million euros ($167 million) in an initial public offering to help fund the European launch of its Resolor...See details»
Movetis - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Movetis uses 4 technology products and services including HTML5, Google Tag Manager, and Adobe Fonts, according to G2 Stack. Movetis is actively using 4 technologies for its website, …See details»
Movetis - Cosmetics Business
Cosmetics Business is the go-to-guide for beauty industry professionals. Expect breaking news, exclusive interviews, regulatory updates and all the latest global business information, in one …See details»